1. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. Issue 5 (25th August 2013) Authors: Harada, N.; Hiramatsu, N.; Oze, T.; Morishita, N.; Yamada, R.; Hikita, H.; Miyazaki, M.; Yakushijin, T.; Miyagi, T.; Yoshida, Y.; Tatsumi, T.; Kanto, T.; Kasahara, A.; Oshita, M.; Mita, E.; Hagiwara, H.; Inui, Y.; Katayama, K.; Tamura, S.; Yoshihara, H. Journal: Journal of viral hepatitis Issue: Volume 21:Issue 5(2014) Page Start: 357 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1. Issue 3 (31st July 2014) Authors: Oze, T.; Hiramatsu, N.; Yakushijin, T.; Yamada, R.; Harada, N.; Morishita, N.; Oshita, M.; Mita, E.; Ito, T.; Inui, Y.; Inada, M.; Tamura, S.; Yoshihara, H.; Imai, Y.; Kato, M.; Miyagi, T.; Yoshida, Y.; Tatsumi, T.; Kasahara, A.; Hayashi, N. Journal: Journal of viral hepatitis Issue: Volume 22:Issue 3(2015) Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗